Also trades as: MDP.TO (TSX) · $vol 0M

$3.34

-0.11 (-3.22%)

Weekly Expected Move ±3.8%

$3 $3 $3 $3 $4

OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Sell · Power 41 · $105.7M mcap · 29M float · 0.054% daily turnover · Short 29% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

Low

Avg Target

High

Based on 1 analyst since Aug 10, 2026 earnings

Analyst Recommendations

Strong Buy: 0Buy: 0Hold: 1Sell: 0Strong Sell: 0

Rating Summary

ConsensusHold

Avg Target$7.00

Analysts1

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-08-11	Industrial Alliance Securities	—	$6	$7	+1	+84.7%	$3.79
2026-06-29	Industrial Alliance Securities	Scott Henry	Initiated	$6	—	+82.0%	$3.16

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

Oct 02, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. MEDXF receives an overall rating of C. Areas of concern: ROE (1/5), ROA (1/5), D/E (1/5), P/E (1/5).

Rating Change History

Date	From	To
2026-08-13	C+	C
2026-05-04	C	C+
2026-04-01	C+	C
2026-02-18	B	C+
2026-02-09	B-	B
2026-01-03	B	B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 14 Grade D

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. MEDXF scores highest in Balance Sheet (48/100) and lowest in Safety (15/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

0.65

Distress Zone

Piotroski F-Score

5/9

✗ ✓ ✗ ✓ ✓ ✓ ✗ ✓ ✗

Beneish M-Score

-3.10

Unlikely Manipulator

Ohlson O-Score

-4.78

Bankruptcy prob: 0.8%

Low Risk

Credit Rating

BB-

Score: 37.5/100

Trend: Deteriorating

Earnings Quality

—

OCF/NI: -7.88x

Accruals: -13.3%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. MEDXF scores 0.65, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. MEDXF scores 5/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. MEDXF's score of -3.10 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. MEDXF's implied 0.8% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. MEDXF receives an estimated rating of BB- (score: 37.5/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

-43.43x

PEG

-0.53x

P/S

1.02x

P/B

2.20x

P/FCF

19.28x

P/OCF

3.80x

EV/EBITDA

6.91x

EV/Revenue

0.88x

EV/EBIT

29.89x

EV/FCF

23.52x

Earnings Yield

-3.34%

FCF Yield

5.19%

Shareholder Yield

0.52%

Graham Number

—

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. MEDXF currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

1.053

NI / EBT

Interest Burden

-0.777

EBT / EBIT

EBIT Margin

0.029

EBIT / Rev

Asset Turnover

0.623

Rev / Assets

Equity Multiplier

3.155

Assets / Equity

ROE

-4.7%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. MEDXF's ROE of -4.7% is driven by financial leverage (equity multiplier: 3.16x). Note: high leverage means ROE is amplified by debt rather than operational performance. A tax burden ratio of 1.05 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate

0.00%

Fair P/E

8.50x

Intrinsic Value

—

Price/Value

—

Margin of Safety

—

Premium

—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$3.34

Median 1Y

$2.42

5th Pctile

$0.64

95th Pctile

$9.15

Ann. Volatility

79.8%

Analyst Target

$7.00

25th–75th percentile 5th–95th percentile Median path Historical Analyst target

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
ROE	-2.0%	-91.0%	-52.1%	-16.1%	15.9%	-51.6%	-56.6%	6.1%	16.2%	25.4%	26.1%	-0.8%	3.9%	8.4%	11.4%	5.4%	1.9%	0.9%	-0.6%	-4.7%	-4.73%
ROA	-23.1%	-15.0%	-5.2%	-2.0%	1.7%	-7.6%	-7.7%	0.8%	2.2%	3.2%	3.8%	-0.1%	0.7%	1.5%	2.3%	1.4%	0.5%	0.3%	-0.2%	-1.5%	-1.50%
ROIC	-14.6%	-19.1%	-20.4%	-18.9%	-21.9%	-1.0%	2.6%	7.6%	12.3%	14.9%	13.6%	-29.1%	13.6%	17.7%	17.7%	19.6%	40.5%	7.0%	3.4%	7.1%	7.12%
ROCE	-24.7%	-15.7%	-3.2%	7.7%	15.1%	3.4%	7.2%	10.8%	15.7%	21.1%	15.5%	15.5%	14.4%	13.1%	14.8%	12.9%	10.3%	9.7%	6.5%	3.1%	3.12%
Gross Margin	40.1%	52.4%	54.1%	49.9%	56.2%	58.3%	55.5%	52.4%	54.6%	53.7%	50.3%	51.2%	54.4%	53.7%	50.7%	50.2%	56.0%	55.7%	53.6%	53.8%	53.84%
Operating Margin	-41.5%	-27.9%	-1.6%	-12.4%	0.1%	7.0%	10.1%	9.5%	15.3%	11.7%	6.2%	3.2%	14.6%	6.2%	12.6%	-4.7%	3.5%	5.6%	6.6%	7.8%	7.84%
Net Margin	-38.1%	56.7%	-5.4%	-26.1%	-6.1%	-9.9%	-5.2%	23.9%	2.1%	-3.6%	-2.1%	2.9%	7.2%	0.4%	2.4%	-2.2%	2.1%	-1.3%	0.3%	-10.9%	-10.85%
EBITDA Margin	-15.1%	80.6%	16.3%	5.0%	6.8%	7.9%	16.5%	21.2%	25.1%	16.5%	14.1%	20.6%	19.6%	12.0%	15.4%	14.9%	18.1%	14.2%	16.4%	2.2%	2.21%
FCF Margin	-28.9%	-23.9%	-23.7%	-11.6%	-0.4%	-3.4%	-3.4%	-1.7%	5.5%	10.9%	17.9%	16.3%	20.6%	18.5%	18.7%	19.7%	16.0%	15.3%	17.3%	3.7%	3.75%
OCF Margin	-6.7%	-1.9%	-1.1%	-1.5%	2.0%	-1.1%	-1.5%	-1.3%	5.8%	11.1%	18.1%	16.6%	20.9%	21.2%	21.3%	22.2%	18.7%	15.6%	17.5%	19.0%	19.00%
ROE 3Y Avg	snapshot only																				-0.43%
ROE 5Y Avg	snapshot only																				-2.41%
ROA 3Y Avg	snapshot only																				-0.15%
ROIC 3Y Avg	snapshot only																				3.01%
ROIC Economic	snapshot only																				6.65%
Cash ROA	snapshot only																				12.81%
Cash ROIC	snapshot only																				29.16%
CROIC	snapshot only																				5.75%
NOPAT Margin	snapshot only																				4.64%
Pretax Margin	snapshot only																				-2.29%
R&D / Revenue	snapshot only																				7.27%
SGA / Revenue	snapshot only																				39.68%
SBC / Revenue	snapshot only																				0.21%

Valuation

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
P/E Ratio	-3.66	-2.39	-5.55	-17.40	13.30	-1.34	-2.83	21.57	8.60	9.33	7.77	-139.43	29.79	20.79	16.76	20.43	93.65	160.17	-251.56	-29.97	-43.427
P/S Ratio	1.52	0.62	0.56	0.65	0.37	0.15	0.31	0.24	0.24	0.38	0.39	0.26	0.30	0.46	0.55	0.42	0.71	0.59	0.69	0.72	1.016
P/B Ratio	9.89	1.93	1.71	2.81	1.75	0.84	2.00	1.17	1.24	2.11	1.55	0.98	1.00	1.46	1.80	0.88	1.43	1.16	1.31	1.46	2.198
P/FCF	-5.27	-2.59	-2.35	-5.63	-86.55	-4.53	-9.14	-14.58	4.39	3.52	2.20	1.62	1.45	2.46	2.92	2.15	4.46	3.83	3.99	19.28	19.284
P/OCF	—	—	—	—	18.97	—	—	—	4.14	3.46	2.18	1.59	1.43	2.15	2.56	1.91	3.82	3.76	3.94	3.80	3.801
EV/EBITDA	-10.32	-31.89	6.48	5.82	3.95	7.89	9.17	5.72	4.08	4.14	3.98	3.41	3.68	4.81	4.93	3.52	5.53	4.47	4.99	6.91	6.909
EV/Revenue	2.08	1.14	1.17	1.24	0.98	0.71	0.87	0.77	0.73	0.82	0.78	0.66	0.65	0.80	0.83	0.55	0.83	0.70	0.79	0.88	0.881
EV/EBIT	-6.24	-5.79	-28.49	13.62	6.17	24.96	26.57	9.88	7.12	6.45	6.19	5.38	5.61	7.77	7.74	6.13	11.40	10.07	13.03	29.89	29.887
EV/FCF	-7.20	-4.78	-4.93	-10.67	-228.03	-20.77	-25.85	-46.15	13.30	7.57	4.33	4.04	3.16	4.31	4.45	2.77	5.20	4.56	4.59	23.52	23.516
Earnings Yield	-27.4%	-41.9%	-18.0%	-5.7%	7.5%	-74.5%	-35.4%	4.6%	11.6%	10.7%	12.9%	-0.7%	3.4%	4.8%	6.0%	4.9%	1.1%	0.6%	-0.4%	-3.3%	-3.34%
FCF Yield	-19.0%	-38.7%	-42.5%	-17.8%	-1.2%	-22.1%	-10.9%	-6.9%	22.8%	28.4%	45.4%	61.8%	68.9%	40.7%	34.3%	46.4%	22.4%	26.1%	25.1%	5.2%	5.19%
EV/OCF	snapshot only																				4.635
EV/Gross Profit	snapshot only																				1.608
Acquirers Multiple	snapshot only																				14.992
Shareholder Yield	snapshot only																				0.52%

Leverage & Solvency

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Current Ratio	1.13	1.02	1.00	1.02	0.97	0.88	0.61	0.87	0.88	0.85	1.11	1.09	1.10	1.01	1.01	0.83	0.81	0.83	1.12	1.19	1.190
Quick Ratio	0.82	0.69	0.65	0.58	0.53	0.51	0.39	0.60	0.60	0.58	0.70	0.63	0.49	0.41	0.49	0.47	0.37	0.38	0.62	0.57	0.569
Debt/Equity	4.51	1.98	2.29	3.08	3.27	3.57	4.26	3.12	3.21	3.32	1.77	1.65	1.44	1.31	1.21	0.71	0.41	0.40	0.49	0.45	0.454
Net Debt/Equity	3.62	1.64	1.88	2.52	2.86	3.00	3.65	2.54	2.51	2.42	1.49	1.47	1.18	1.10	0.95	0.25	0.24	0.22	0.20	0.32	0.321
Debt/Assets	0.36	0.35	0.38	0.39	0.42	0.43	0.45	0.43	0.44	0.43	0.33	0.32	0.32	0.30	0.27	0.22	0.14	0.14	0.16	0.15	0.151
Debt/EBITDA	-3.44	-17.68	4.13	3.37	2.81	7.34	6.90	4.81	3.49	3.04	2.32	2.28	2.43	2.47	2.16	2.21	1.38	1.29	1.60	1.76	1.758
Net Debt/EBITDA	-2.76	-14.64	3.39	2.75	2.45	6.17	5.93	3.91	2.73	2.21	1.95	2.04	1.99	2.07	1.70	0.79	0.79	0.72	0.66	1.24	1.243
Interest Coverage	-2.47	-1.38	-0.26	0.57	1.05	0.21	0.25	0.62	0.81	0.97	0.98	1.04	1.13	1.19	1.40	1.18	1.02	1.06	1.03	0.56	0.563
Equity Multiplier	12.46	5.72	5.97	7.83	7.77	8.40	9.48	7.19	7.34	7.64	5.43	5.14	4.52	4.44	4.41	3.30	2.90	2.85	2.97	3.01	3.006
Cash Ratio	snapshot only																				0.122
Debt Service Coverage	snapshot only																				2.434
Cash to Debt	snapshot only																				0.293
FCF to Debt	snapshot only																				0.167
Defensive Interval	snapshot only																				159.7 days

Efficiency & Turnover

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Asset Turnover	0.56	0.58	0.52	0.53	0.59	0.66	0.70	0.72	0.77	0.77	0.75	0.71	0.69	0.67	0.72	0.66	0.70	0.71	0.66	0.62	0.623
Inventory Turnover	2.74	2.67	2.47	2.15	2.20	2.18	2.31	2.17	2.23	2.25	2.19	2.00	1.69	1.58	1.69	1.57	1.40	1.35	1.40	1.31	1.310
Receivables Turnover	4.42	5.25	3.49	4.83	5.20	5.93	5.70	6.11	5.74	6.01	5.44	4.93	5.55	5.87	6.02	5.85	8.30	8.30	7.68	7.11	7.109
Payables Turnover	1.61	1.61	1.38	2.88	1.58	1.49	1.72	4.33	1.73	1.72	1.53	5.98	1.47	1.39	1.25	7.68	1.33	1.31	1.10	6.44	6.440
DSO	83	70	104	76	70	62	64	60	64	61	67	74	66	62	61	62	44	44	48	51	51.3 days
DIO	133	137	148	170	166	168	158	168	164	162	167	183	216	231	215	233	261	270	260	279	278.7 days
DPO	226	226	265	127	231	245	213	84	210	212	238	61	248	263	291	48	273	279	331	57	56.7 days
Cash Conversion Cycle	-10	-20	-12	119	5	-16	9	143	17	11	-4	196	34	30	-15	248	31	35	-23	273	273.3 days
Fixed Asset Turnover	snapshot only																				235.384
Operating Cycle	snapshot only																				330.0 days
Cash Velocity	snapshot only																				15.228
Capital Intensity	snapshot only																				1.483

Growth (YoY)

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Revenue	24.0%	14.4%	-8.2%	-0.8%	10.8%	23.5%	39.9%	40.9%	41.4%	29.2%	16.0%	4.6%	-6.7%	-12.1%	-5.3%	-4.2%	-2.9%	-0.6%	-9.2%	-8.3%	-8.31%
Net Income	-4.0%	-1.3%	63.5%	89.7%	1.1%	45.5%	-52.7%	1.4%	41.6%	1.5%	1.5%	-1.2%	-66.6%	-53.2%	-39.4%	11.5%	-26.2%	-83.4%	-1.1%	-2.1%	-2.07%
EPS	-2.8%	-74.1%	73.3%	91.1%	1.1%	46.8%	-50.4%	1.4%	39.6%	1.5%	1.4%	-1.2%	-72.4%	-60.9%	-40.6%	10.3%	-44.0%	-87.4%	-1.1%	-1.9%	-1.92%
FCF	-18.9%	-21.1%	-12.0%	-50.1%	98.4%	82.5%	80.0%	79.7%	19.1%	5.1%	7.1%	11.2%	2.5%	49.3%	-1.3%	15.5%	-24.4%	-17.8%	-16.2%	-82.5%	-82.54%
EBITDA	-8.2%	-1.7%	2.5%	2.3%	2.4%	4.1%	-25.8%	-10.6%	2.1%	1.9%	1.4%	49.9%	-7.9%	-26.7%	-18.1%	-23.0%	-17.4%	-6.5%	-14.5%	-24.7%	-24.70%
Op. Income	-1.9%	-7.0%	-8.8%	-9.1%	20.5%	94.4%	1.1%	1.5%	2.6%	17.3%	4.3%	41.8%	-20.1%	-42.9%	-19.5%	-23.8%	-48.6%	-39.6%	-73.3%	-29.0%	-29.04%
OCF Growth	snapshot only																				-21.47%
Asset Growth	snapshot only																				-14.29%
Equity Growth	snapshot only																				-6.05%
Debt Growth	snapshot only																				-40.12%
Shares Change	snapshot only																				15.83%

Growth (CAGR)

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Revenue 3Y	1.3%	1.1%	60.6%	44.2%	32.6%	26.9%	28.6%	27.5%	24.7%	22.2%	14.2%	13.5%	13.5%	11.9%	15.4%	12.2%	8.6%	4.1%	-0.1%	-2.8%	-2.78%
Revenue 5Y	—	—	—	—	—	—	1.2%	1.0%	82.2%	69.7%	46.4%	34.6%	25.2%	18.4%	18.5%	15.7%	12.0%	9.8%	5.1%	5.1%	5.13%
EPS 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-40.0%	—	—	—	—
EPS 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-29.6%	—	—	—	—
Net Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA 3Y	—	—	—	12.1%	1.6%	22.6%	38.6%	68.1%	1.2%	79.3%	—	—	—	—	12.9%	1.0%	-8.1%	25.4%	18.4%	-4.6%	-4.58%
EBITDA 5Y	—	—	—	—	—	—	—	—	—	—	—	4.0%	74.0%	31.2%	38.9%	40.6%	50.2%	31.6%	—	—	—
Gross Profit 3Y	1.3%	1.0%	52.5%	35.9%	27.3%	23.2%	26.2%	27.0%	25.3%	22.5%	14.2%	13.5%	15.9%	14.6%	17.8%	14.3%	8.1%	2.9%	-1.0%	-3.2%	-3.23%
Gross Profit 5Y	—	—	—	—	—	—	1.3%	1.1%	86.7%	72.1%	43.9%	31.6%	21.8%	15.2%	15.9%	14.1%	11.2%	9.5%	5.5%	6.0%	5.95%
Op. Income 3Y	—	—	—	—	—	—	—	—	—	—	79.3%	—	—	—	—	—	—	—	4.8%	-8.5%	-8.49%
Op. Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	4.4%	—	—
FCF 3Y	—	—	—	—	—	—	—	—	74.6%	1.4%	—	—	—	—	—	—	—	—	—	—	—
FCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	69.7%	78.1%	—	—	—
OCF 3Y	—	—	—	—	—	—	—	—	60.5%	1.4%	—	57.1%	—	—	—	—	1.3%	—	—	—	—
OCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	64.5%	74.4%	—	31.4%	31.36%
Assets 3Y	1.7%	1.7%	18.7%	17.9%	16.0%	18.6%	19.7%	9.5%	10.0%	11.0%	5.1%	1.6%	1.0%	1.9%	1.9%	7.3%	4.1%	1.6%	1.9%	-3.0%	-2.99%
Assets 5Y	—	—	—	—	—	—	79.5%	86.4%	89.2%	88.0%	14.2%	12.9%	11.0%	11.2%	11.4%	6.9%	4.2%	4.2%	2.3%	-0.2%	-0.17%
Equity 3Y	84.7%	—	-18.0%	-13.9%	-12.2%	-13.5%	-12.4%	-2.6%	3.9%	5.4%	90.1%	18.9%	41.6%	10.9%	12.7%	43.1%	44.5%	45.7%	50.1%	29.7%	29.71%
Book Value 3Y	24.2%	—	-28.1%	-28.1%	-20.6%	-18.9%	-22.0%	-15.8%	-7.1%	-6.1%	60.1%	5.7%	30.6%	2.9%	4.6%	28.4%	23.1%	24.2%	27.9%	14.7%	14.67%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Revenue Stability	0.98	0.93	0.82	0.88	0.95	0.98	0.94	0.96	0.97	0.98	0.93	0.94	0.92	0.87	0.91	0.86	0.73	0.62	0.47	0.39	0.386
Earnings Stability	0.72	0.73	0.35	0.13	0.04	0.47	0.34	0.00	0.01	0.01	0.09	0.11	0.17	0.20	0.39	0.32	0.29	0.51	0.65	0.44	0.440
Margin Stability	0.90	0.91	0.92	0.92	0.92	0.91	0.93	0.91	0.94	0.95	0.94	0.93	0.93	0.92	0.94	0.95	0.98	0.98	0.98	0.97	0.972
Rev. Growth Consistency	1.00	1.00	0.00	0.00	1.00	1.00	0.50	0.50	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.000
Earn. Growth Consistency	0.00	0.00	0.50	0.50	0.50	0.50	0.00	1.00	1.00	1.00	0.50	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.00	0.00	0.000
FCF Positive Streak	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1
Earnings Persistence	0.50	0.50	0.50	0.50	0.20	0.82	0.50	0.20	0.50	0.20	0.20	0.20	0.50	0.50	0.50	0.20	0.90	0.50	0.20	0.20	0.200
Earnings Smoothness	—	—	—	—	—	—	—	—	0.66	—	—	—	0.00	0.27	0.51	—	0.70	0.00	—	—	—
ROE Trend	-2.43	-0.53	2.05	0.70	1.64	0.00	1.72	0.91	1.43	0.94	0.71	0.05	-0.10	0.27	0.36	0.02	-0.07	-0.14	-0.16	-0.07	-0.067
Gross Margin Trend	-0.08	-0.08	-0.06	-0.05	0.01	0.04	0.04	0.04	0.04	0.02	0.01	0.00	-0.02	-0.02	-0.02	-0.02	-0.01	-0.00	0.01	0.02	0.023
FCF Margin Trend	-0.25	-0.22	-0.21	-0.05	0.13	0.08	0.09	0.08	0.20	0.25	0.31	0.23	0.18	0.15	0.11	0.12	0.03	0.01	-0.01	-0.14	-0.142
Sustainable Growth Rate	—	—	—	—	15.9%	—	—	6.1%	16.2%	25.4%	26.1%	—	3.9%	8.4%	11.4%	5.4%	1.9%	0.9%	—	—	—
Internal Growth Rate	—	—	—	—	1.7%	—	—	0.8%	2.2%	3.3%	4.0%	—	0.7%	1.5%	2.4%	1.4%	0.5%	0.3%	—	—	—

Cash Flow Quality

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
OCF/Net Income	0.16	0.07	0.11	0.41	0.70	0.10	0.14	-1.18	2.08	2.70	3.57	-87.45	20.78	9.67	6.56	10.70	24.52	42.63	-63.83	-7.88	-7.884
FCF/OCF	4.28	12.75	21.11	7.54	-0.22	3.02	2.21	1.25	0.94	0.98	0.99	0.99	0.99	0.87	0.88	0.89	0.86	0.98	0.99	0.20	0.197
FCF/Net Income	snapshot only																				-1.554
OCF/EBITDA	snapshot only																				1.491
CapEx/Revenue	22.1%	22.1%	22.5%	10.1%	2.4%	2.3%	1.9%	0.3%	0.3%	0.2%	0.2%	0.2%	0.2%	2.7%	2.6%	2.5%	2.7%	0.3%	0.2%	15.3%	15.26%
CapEx/Depreciation	snapshot only																				1.557
Accruals Ratio	-0.19	-0.14	-0.05	-0.01	0.00	-0.07	-0.07	0.02	-0.02	-0.05	-0.10	-0.12	-0.14	-0.13	-0.13	-0.13	-0.13	-0.11	-0.12	-0.13	-0.133
Sloan Accruals	snapshot only																				0.108
Cash Flow Adequacy	snapshot only																				1.245

Dividends & Buybacks

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Payout Ratio	—	—	—	—	0.0%	—	—	0.0%	0.0%	0.0%	0.0%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—	—
FCF Payout Ratio	—	—	—	—	—	—	—	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Total Payout Ratio	—	—	—	—	0.0%	—	—	0.0%	0.0%	0.0%	0.0%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—	—
Div. Increase Streak	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.5%	0.52%
Net Buyback Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-16.6%	-25.4%	-23.3%	-15.9%	-0.0%	-41.7%	-25.4%	-31.4%	-27.5%	0.0%	0.00%
Total Shareholder Return	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-16.6%	-25.4%	-23.3%	-15.9%	-0.0%	-41.7%	-25.4%	-31.4%	-27.5%	0.0%	0.00%

DuPont Factors

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Tax Burden (NI/EBT)	0.90	0.77	0.53	0.75	1.90	1.18	1.26	-0.24	-1.26	-4.73	-6.74	-2.02	0.97	1.52	1.12	1.56	5.20	0.93	10.88	1.05	1.053
Interest Burden (EBT/EBIT)	1.39	1.70	4.59	-0.55	0.09	-3.43	-2.64	-0.60	-0.22	-0.07	-0.06	0.01	0.09	0.14	0.27	0.15	0.02	0.06	-0.00	-0.78	-0.777
EBIT Margin	-0.33	-0.20	-0.04	0.09	0.16	0.03	0.03	0.08	0.10	0.13	0.13	0.12	0.12	0.10	0.11	0.09	0.07	0.07	0.06	0.03	0.029
Asset Turnover	0.56	0.58	0.52	0.53	0.59	0.66	0.70	0.72	0.77	0.77	0.75	0.71	0.69	0.67	0.72	0.66	0.70	0.71	0.66	0.62	0.623
Equity Multiplier	8.45	6.08	10.06	8.04	9.62	6.83	7.37	7.47	7.53	7.97	6.82	6.01	5.68	5.72	4.89	3.97	3.52	3.46	3.53	3.16	3.155

Per Share

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
EPS (Diluted TTM)	$-1.62	$-0.99	$-0.36	$-0.14	$0.12	$-0.53	$-0.55	$0.06	$0.16	$0.24	$0.24	$-0.01	$0.04	$0.09	$0.14	$0.08	$0.02	$0.01	$-0.01	$-0.07	$-0.07
Book Value/Share	$0.60	$1.23	$1.17	$0.89	$0.88	$0.85	$0.77	$1.01	$1.12	$1.06	$1.22	$1.24	$1.33	$1.34	$1.34	$1.89	$1.64	$1.62	$1.61	$1.53	$1.51
Tangible Book/Share	$-4.18	$-3.38	$-3.31	$-3.48	$-3.40	$-3.31	$-3.32	$-2.63	$-2.81	$-2.75	$-1.95	$-1.80	$-1.65	$-1.59	$-1.47	$-1.07	$-0.83	$-0.77	$-0.70	$-0.73	$-0.73
Revenue/Share	$3.88	$3.83	$3.61	$3.84	$4.13	$4.62	$4.98	$4.88	$5.76	$5.84	$4.79	$4.62	$4.45	$4.28	$4.44	$3.92	$3.28	$3.22	$3.07	$3.10	$3.25
FCF/Share	$-1.12	$-0.92	$-0.85	$-0.45	$-0.02	$-0.16	$-0.17	$-0.08	$0.32	$0.64	$0.86	$0.75	$0.92	$0.79	$0.83	$0.77	$0.53	$0.49	$0.53	$0.12	$-0.04
OCF/Share	$-0.26	$-0.07	$-0.04	$-0.06	$0.08	$-0.05	$-0.08	$-0.07	$0.34	$0.65	$0.87	$0.77	$0.93	$0.91	$0.95	$0.87	$0.61	$0.50	$0.54	$0.59	$0.43
Cash/Share	$0.53	$0.42	$0.48	$0.50	$0.37	$0.48	$0.46	$0.59	$0.78	$0.95	$0.34	$0.21	$0.35	$0.29	$0.34	$0.87	$0.29	$0.29	$0.46	$0.20	$0.17
EBITDA/Share	$-0.78	$-0.14	$0.65	$0.82	$1.03	$0.41	$0.47	$0.66	$1.03	$1.16	$0.93	$0.89	$0.79	$0.71	$0.75	$0.61	$0.49	$0.50	$0.49	$0.40	$0.40
Debt/Share	$2.70	$2.43	$2.69	$2.75	$2.88	$3.03	$3.28	$3.17	$3.60	$3.53	$2.16	$2.04	$1.91	$1.76	$1.62	$1.34	$0.68	$0.65	$0.78	$0.70	$0.70
Net Debt/Share	$2.17	$2.01	$2.20	$2.25	$2.52	$2.55	$2.81	$2.58	$2.82	$2.57	$1.82	$1.83	$1.57	$1.47	$1.28	$0.48	$0.39	$0.36	$0.32	$0.49	$0.49

Academic Models

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.649
Altman Z-Prime	snapshot only																				-0.071
Piotroski F-Score	2	3	3	4	5	4	3	4	5	5	7	5	5	6	5	5	5	5	5	5	5
Beneish M-Score	-3.16	-3.12	-3.16	-2.58	-2.62	-2.54	-2.46	-1.95	-1.92	-2.34	-2.73	-2.94	-3.67	-3.55	-3.38	-3.50	-3.15	-3.10	-3.19	-3.10	-3.097
Ohlson O-Score	snapshot only																				-4.778
Net-Net WC	snapshot only																				$-1.08
EVA	snapshot only																				$-1863450.00

Credit

Metric	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Q4'26	Current
Credit Rating	snapshot only																				BB-
Credit Score	19.90	21.70	17.35	21.20	24.45	16.35	9.30	18.35	22.25	24.35	38.00	39.90	41.50	41.50	44.65	46.75	49.75	49.75	49.75	37.50	37.500
Credit Grade	snapshot only																				13
Credit Trend	snapshot only																				-9.250
Implied Spread (bps)	snapshot only																				550.000

MEDXF OTC

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Sign in to InsiderStreet